Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30 pat...
Novartis discontinued a Phase 1 protein-based oncology candidate after it failed to produce tumor shrinkage in 30 patients with advanced solid tumors.
Why it mattersPhase 1 failure in 30 solid tumor patients should prompt investors to de-risk protein oncology commitments.